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 Medications administered by anesthesia health care providers and subsequently excreted 
into the water supply system have the potential to affect ecological systems. Presently, there is a 
lack of literature examining which medications or metabolites enter the waste stream. Further, 
assessments of their potential environmental impact are often unknown or simply not considered 
as an externality of medical practice. Recent work examining the practice of anesthesiology has 
explored the solid waste stream, and the global warming potential of anesthetic gases, however 
the potential aquatic impacts remain unexplored. To address the potential for waterborne 
pollution and environmental toxicity, we extracted the total intravenous medications (by mass) 
administered by anesthesiologists in 2017 at The University of Vermont Medical Center 
(UVMMC), a mid-size regional Level 1 trauma center in Burlington, VT. The most commonly 
administered medications were: cefazolin, propofol, acetaminophen, sugammadex and lidocaine.  
To estimate the amount of each medication that entered the wastewater stream, we used 
published metabolism profiles to adjust from the total amount administered to the amount 
excreted unchanged or as prominent metabolites. For each medication we reviewed existing 
literature concerning their environmental fate and impacts in water. Due to the constraints of 
current knowledge, it is not possible to determine the exact fate and impacts of these drugs. 
Some medications, like propofol, have the potential for significant bioaccumulation and 
persistence.  Others, such as lidocaine and acetaminophen, have short half-lives in the 
environment but their constant delivery and excretion result in pseudo-persistence. The current 
literature mostly assesses acute exposure at doses higher than could be expected in the 
environment on select species. While significant toxicities across a variety of species have been 
found repeatedly, chronic low dose exposures require further study for all the medications 
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discussed.  Finally, multi-drug impacts are likely to be more impactful than single-drug 
toxicities. While we cannot state definitive impacts, the pharmaceuticals most used in 
anesthesiology have a clear toxic potential and future studies should more closely examine the 
relative contribution of anesthesia to pharmaceutical pollution, as well as points of intervention 
for minimizing these unintended consequences of healthcare delivery. 
Introduction 
As large-scale industrial facilities that operate 24/7 every day of the year with a mandate 
of supporting human health, hospitals have an opportunity and responsibility to promote 
practices that minimize environmental damage [1,2]. Healthcare facilities have been estimated to 
produce almost 10% of total greenhouse gases in the U.S. [3], and at over 4 billion tons of waste 
each year, the healthcare industry as a whole produces is the second largest source of waste in 
the U.S. [4]. Many calls to action have been placed to reduce the unintended environmental and 
public health consequences of medical care [5-7], and efforts by several national and 
international organizations—including Health Care Without Harm, Practice Greenhealth, the 
Green Guide for Healthcare, and the Healthier Hospitals Initiative—are already underway to 
reduce healthcare’s ecological footprint. Surgery and the entire perioperative process are areas 
that appear to remain major drivers of resource use and pollution in healthcare.  
 Within healthcare, surgical departments and operating rooms (OR) are extremely costly, 
accounting for about 40% of hospital costs. Although perioperative processes account for 40% of 
costs, they may actually be responsible for 70% of hospital wastes [8]. Previous research on the 
environmental consequences of medical care suggest that high costs of care correspond, in part, 
to a heavy reliance on medical supplies, including single-use materials which each have 
potentially large ecological footprints that accumulate throughout the supply chain from resource 
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extraction, manufacturing, processing, packaging, transport, and disposal [5,9].  ORs use a wide 
variety of resources from water and plastics to anesthesia gases, all of which have different 
environmental impacts. Further, lifecycle considerations given the choice between disposable 
and washable equipment carries its own complexity. Previous studies have found that a single 
procedure could create more waste than that produced over a week by a family of 4 [10]. A 
single surgeon scrubbing in for a procedure can use 50 liters of water [11]. 
OR management could become more sustainable should hospital systems focus on and 
mitigate any potential waste streams. For example, previous work analyzing hand surgery found 
that eliminating just a handful of extraneous items from disposable packs used in those 
procedures accounted for over $40,000 in annual savings [12]. Also, a larger commercial effort 
to recycle OR equipment saved over 2000 tons of landfill waste and nearly $140 million in 2008 
alone [12].  Presumably, the reduction of materials consumed in the OR has a three-fold benefit: 
it saves the hospital money and thus reduces the cost of procedures; decreased procedural costs 
lower health care expenses, possibly stemming the ballooning cost of health in the U.S.; and 
finally, it mitigates the environmental externalities inherent to the provision of perioperative 
care. 
While previous work has analyzed the impacts of anesthesia gases and solid waste 
resulting from ORs [13-16], there is a dearth of literature regarding the intravenous medications 
used and their impact on surface waters. Medications, given in high quantities during the 
perioperative process, are metabolized and excreted into hospital and municipal waste water 
systems.  Although hospital wastewater is typically  treated via municipal wastewater treatment 
facilities, these facilities are not designed to remove the myriad of chemicals and agents that are 
administered in healthcare [17] and are known sources of pharmaceuticals in the environment 
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[18-20]. In national reconnaissance studies, pharmaceuticals have been detected in 80% of 
surface waters tested in the U.S. [21] and 100% of 25 large municipal drinking water systems 
[22]. 
While the relative contribution of various sources is unknown, hospital wastewater plays 
a role in the pharmaceutical pollution of surface waters. In order to examine the potential 
environmental impacts of those medications on its receiving waters of Lake Champlain (which 
lies between Vermont and New York), we extracted the total intravenous medications (by mass) 
administered by anesthesiologists in 2017 at The University of Vermont Medical Center 
(UVMMC), a mid-size regional Level 1 trauma center in Burlington, VT.  All medications are 
tracked on PICIS (Picis Clinical Solutions, Inc., Wakefield, MA).  Wastewater from the 
UVMMC is treated by the Burlington Department of Public Works prior to being released into 
Lake Champlain.  Of note, Lake Champlain is the primary source for Burlington’s public 
drinking water supply. 
Discussion 
 In 2017, anesthesia health care providers administered over 35 kilograms of medications 
with varied potentials for concern at the University of Vermont Medical Center, the five most 
common medications were Cefazolin, Acetaminophen, Sugammadex, Lidocaine and Propofol 
(Table 1). The Burlington’s wastewater treatment plants process all of the hospital effluent. 
These plants use conventional activated sludge technologies and are occasionally unable to 





Cefazolin, an antibiotic administered for surgical prophylaxis, represents the largest drug 
by mass administered during the perioperative process at UVMMC in 2017. Cefazolin was given 
13,003 times for a total of 23.81 kg, 20 kg more than the next highest mass drug. Not only is 
cefazolin administered frequently, but it is also one of the most wasted and discarded antibiotics 
[25]. This suggests that the total amount of cefazolin that enters the waste-stream from the 
practice of anesthesia could be significantly greater than the total administered to patients due to 
cefazolin that is discarded rather than administered to patients. Cefazolin does not undergo 
significant metabolism and is excreted by the kidneys unchanged [26]. Thus, potentially all of 
the 23.81 kg found their way into the wastewater systems. Cefazolin has been found in general 
hospital water effluent at concentrations around 6.2 mg/L and may be reaching the environment 
in significant quantities [27]. 
Despite its relatively long history, the environmental effects of cefazolin have not been 
thoroughly studied [28]. Cefazolin has been shown not to harm green microalgae (Selenastrum 
capriconutum and Chlorella vulgaris) – cornerstones of the aquatic ecosystems [29]. On the 
other hand, in the aquatic environment, cefazolin is susceptible to photo-transformation and 
chlorination into toxic byproducts [30].  Further, cefazolin is known to be highly teratogenic in 
zebra fish at 100 µg/mL (as compared to the 6.2 µg/mL found in hospital effluent) and thus, may 
have significant impacts on aquatic environments [31,30]. 
Current conventional wastewater treatment does not fully remove cefazolin and other 
cephalosporins. Cefazolin has been measured entering wastewater plants from 0.08 to 8.79 
µg/mL and leaving those plants at levels as high as 3.8 µg/mL [32]. While these measurements 
came from Hong Kong which is clearly quite different from Burlington, Vermont they highlight 
the incomplete removal of cefazolin by wastewater treatment plants. Two wastewater treatment 
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methods - photolysis and adsorption – can remove cefazolin; however, results are inconsistent 
and further technologies may be required for full removal from wastewaters [30]. Although 
photolysis is a technology designed to remove chemicals, its use may be unwise in the context of 
cefazolin removal given the potential for toxic by-products.  Despite unclear aquatic-
environmental concerns, the growing numbers of antibiotic-resistant bacteria in wastewater 
treatment plants should prove alarming [30]. 
Propofol 
Propofol was the second most administered drug by mass at 3.70 kg distributed in 48,500 
doses. The amount of propofol in the hospital waste-stream is likely substantially larger as it is 
one of the most wasted medications whereby 1/3 to ½ of the drug is usually discarded rather than 
administered to patients [25,33]. As one of the cornerstone drugs of anesthesia, understanding its 
potential impact is crucial. Less than 1% of propofol is excreted unchanged while about 60% 
undergoes hepatic glucuronidation and the remainder is oxidized into several different quinol 
products [34],[35]. Therefore, a maximum of 37 g of unchanged propofol could have ended up 
into the water system.  
Although propofol levels in French hospital wastewater streams approach 17.5 µg/L, it 
appears that the drug does reach wastewater treatment plants [36]. However, other studies show 
higher levels of propofol leaving wastewater treatment plants than in the incoming waters, 
potentially due to de-glucuronidation [37]. Approximately 60 times more propofol is excreted in 
the glucuronidated form than the native formulation.  Therefore, it is possible that any measured 
levels are drastically underestimating the potential amount in waters. Given the significant 
amount of glucuronidated propofol, the contribution from anesthesia services at the UVMMC 
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may have up to an additional 2.22 kg from de-glucuronidation in addition to the original 37 g of 
pure propofol. 
While the current evidence on propofol reaching the environment is sparse, there are 
significant concerns regarding its potential environmental impact. Propofol may bioaccumulate 
in organisms due to its fat solubility, although studies show lower than theoretically expected 
results [38]. Ecotoxicity testing has found impacts on a large range of species from growth 
inhibition and death of algae, to acute toxicity in small crustaceans (Daphnia magna), and 
freshwater fish (blue gill sunfish and rainbow trout) [38]. There are limited data regarding 
chronic exposure, although laboratory studies show it impacts the survival, growth and 
reproduction of Daphnia magna [38]. Understanding long-term exposure is of particular 
importance because propofol is not readily degraded [38]. Conventional wastewater treatment 
methods, including aerobic removal by activated sludge or anaerobic digesters are minimally 
effective [38]. 
Once in the aquatic environment, propofol is not significantly photolyzed in water [38]. 
In fact, propofol must be incinerated at >1000°C for over 2 seconds – an impractical target to 
reach via any standard public water treatment method – to fully remove the drug 
[25].Additionally, propofol is highly mobile in soils and therefore, may accumulate significantly 
both on land if deposited via biosolid waste, as well as in water near wastewater release points 
[38].Aquatic accumulation is particularly likely given the estimated aquatic half-life of greater 
than 1 year [38]. In sum, propofol has the potential for bioaccumulation, has both acute and 
chronic aquatic toxicity, and does not readily degrade [25,38]. The current manufacturer 
assessment states that the overall environmental risk is predicted to be low based on less than 1% 
of propofol being excreted unchanged [38].  Again, the potential for significant amounts of the 
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~60% of excreted glucuronidated propofol to become propofol in the environment suggests that 
the current impact could be 60 times greater than currently estimated. 
Acetaminophen 
In 2017, the anesthesia health care service administered a total of 3.35 kg of 
acetaminophen over 4478 doses. Acetaminophen is mostly metabolized by kidneys with only 5% 
excreted unchanged. Therefore, we estimated that 170 grams of pure acetaminophen (equivalent 
to 523 standard over the counter pills) were excreted into the water as a result of the practice of 
anesthesia at UVMMC.  Drug metabolism is distributed an average as 55% apap-glucose, which 
is divided between renal and biliary excretion; 37% as apap-sulfate excreted through the kidneys, 
and 7% becoming n-acetyl-p-benzoquinone-imine (NAPQI). NAPQI then undergoes a set of 
reactions concluding with apap-mercapturic acid [39]. 
Although the perioperative arena only accounts for a small portion of acetaminophen 
delivered in a hospital system, acetaminophen is one of the most prescribed drugs across the 
world and is available over the counter in many countries - further necessitating an 
understanding of its environmental impacts as well as the large amount taken as an over-the-
counter medication. Acetaminophen has been found in waters across the US, Europe and the 
world in concentration as high as 65 µg/L in Great Britain [40]. In the US, it has been detected in 
24% of stream water samples [41] and it has even been found to survive into drinking waters 
[42]. 
Due to its frequency, persistence and toxic potential, acetaminophen has been labeled a 
priority drug for water cycle assessments and is generally considered to have significant 
ecological hazard potential [41,43,44]. While it is well-established that acetaminophen causes 
hepatotoxicity in humans and mammals at high doses, the aquatic impacts are not as well studied 
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[43]. Acetaminophen has been found to be acutely toxic to nearly all species, including bacteria, 
algae and macrophytes and crustaceans, in a standard battery of aquatic environmental tests 
organisms including bacteria, microalgae, aquatic plants, and crustaceans [40].Acetaminophen 
has been found to be specifically neurotoxic to freshwater shrimp and planarians [40]. Of note, 
the toxicity was elicited at lower doses in the crustaceans than the microorganisms.  While these 
results were seen at doses orders of magnitude greater than currently documented in wastewaters, 
the potential for non-fatal or non-growth arresting chronic impacts at lower doses is significant 
and has been demonstrated at doses in the µg/L range in marine and freshwater clams [43,40]. 
Studies of these bivalves are particularly important as they are crucial elements in ecosystems 
and are also filter feeders and thus accumulate higher levels of environmental pollutants [43]. 
Finally, acetaminophen disrupts the endocrine systems and inhibits growth in laboratory studies, 
highlighting the importance of sub-lethal subacute exposure [45,46]. While acetaminophen has a 
significant potential ecotoxicity, results and concentrations needed to elicit toxicity vary widely 
in the literature, and more assessments of non-vertebrates, the foundation of many ecosystems, 
are needed [40]. 
While acetaminophen is unlikely to survive more than 15 days in the environment [45], 
pseudo-persistence is a major concern since effluent release areas are constantly bathed with low 
levels of medications leading to chronic exposure [47-50]. In some regions, 15 days of survival 
is more than enough time for acetaminophen to distribute across a wide area. Even after 
degradation, certain photolysis products of acetaminophen may be more toxic than 
acetaminophen itself, thus further complicating a comprehensive understanding of 
acetaminophen’s environmental impact [51]. Additionally, wastewater effluent also contains 
countless other medications; and acetaminophen may amplify the toxicity of other drugs 
13 
 
[40].While acetaminophen clearly survives into the environment, conventional activated sludge 
(and more advanced technologies such as membrane bioreactors) have been shown to remove 
>98% of the drug [52-54]. However, given the levels of acetaminophen in the environment is it 
likely that much higher removal efficiency is needed to truly prevent its ecological impact.  
Sugammadex 
Approved by the Federal Drug Administration in 2015, sugammadex has quickly grown 
to become one of the most used drugs among anesthesia health care providers. In 2017, 1.38 kg 
of sugammadex was administered over 7,073 doses at UVMMC. Sugammadex is renally 
eliminated unchanged and it environmental impact is unknown [55]. There is currently a lack of 
literature regarding its presence in wastewater streams, its toxicity, and its environmental impact. 
However, it is clear that sugammadex may have significant impacts due to its ability to bind to 
estrogen and progesterone [56]. Its ability to bind these hormones in humans is so significant that 
alternate forms of birth control are needed for 7 days after a single dose of sugammadex.  With 
its potential as an endocrine disruptor are warranted, further research into the environmental 
impacts and especially its potential to be an endocrine disruptor are warranted. Currently, it is 
unclear whether it reaches the aquatic environment and whether sugammadex is a source of 
environmental externalities from the practice anesthesia. 
Lidocaine 
Lidocaine was administered nearly 16,000 times for a total of 1.02 kg by UVMMC 
anesthesiologists in 2017. Lidocaine is excreted in several different forms. Ten percent is 
excreted unchanged by the kidneys, while 90% is metabolized. Lidocaine metabolism produces 
mostly monoethylglycinexylidine (MEGX), the major metabolite, and 2,6-xylidine as its minor 
product. Both MEGX and 2,6-xylidine undergo renal elimination [57]. MEGX is also further 
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metabolized into the potentially carcinogenic 2,6-xylidine [58]. We estimate that 102 grams of 
pure lidocaine would have been excreted and upwards of 500 g of MEGX. 
Lidocaine and its metabolites have been found in both wastewater and in the environment 
as they are only partially removed by wastewater treatment [58]. While the metabolites (MEGX 
and 2,6-xylidine) have been found occasionally in wastewater, lidocaine is not fully removed by 
treatment and has been found in surface waters and not just waste-streams [58]. While traditional 
activated sludge treatment is not fully effective against lidocaine, both PAC/GAC absorption and 
ozonation are effective and thus any potential impacts of lidocaine may be mitigated or 
prevented [59]. However, lidocaine does not appear to survive long enough in the environment to 
reach groundwater stores [58]. 
Despite this presumed potential for environmental degradation, lidocaine has been found 
at least 3 km downstream from a wastewater effluent release location [58]. This indicates the 
potential for environmental persistence particularly near any release points. While lidocaine may 
be persistent, it is unlikely to bio-accumulate in organisms due to its low lipid solubility. Short-
term tests have not found significant aquatic toxicity from lidocaine; but the long-term studies at 
the release points and surrounding environments are lacking [60]. Within the Lake Champlain 
waterways, where the discharge ends in a lake, accumulation over time may be significant.  
Conclusion 
 Medications administered by anesthesia health care providers and subsequently excreted 
into the water supply system have the potential to affect ecological systems. Currently, it is not 
possible to definitively describe the fate of these chemicals in the environment. Some 
medications, like propofol, have the potential for significant bioaccumulation and persistence.  
Other drugs, such as lidocaine and acetaminophen, have short half-lives in the environment but 
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their constant delivery and excretion result in pseudo-persistence. The current literature mostly 
assesses acute exposure at doses higher than could be expected in the environment on select 
species. While significant toxicities across a variety of species have been found repeatedly, 
chronic low dose exposures require further study for all the medications discussed.  Finally, 
multi-drug impacts are likely to be more impactful than single-drug toxicities [61,62,49,63,50]. 
While the current literature does not allow for definitive statements regarding the impacts of 
anesthetics in the aquatic environment, they have a clear toxic potential and future studies should 
more closely examine the relative contribution of anesthesia to pharmaceutical pollution, as well 
as points of intervention for minimizing these unintended consequences of healthcare delivery. 
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Table 1.  Table of the most common drugs administered by the anesthesia service at the 
University of Vermont Medical Center in 2017. 
Drug mg kg Doses 
Cefazolin 23,807,414 23.80741 13,003 
Propofol 3,696,145.5 3.696146 48,500 
Acetaminophen IV 3,350,373.5 3.350374 4,478 
Sugammadex 1,384,146.6 1.384147 7,073 
Lidocaine 2% IV 1,019,456 1.019456 15,887 
Rocuronium 560,887.73 0.560888 17,323 
Ketamine IV 334,560.6 0.334561 18,898 
Succinylcholine Chloride 298,443 0.298443 2,584 
Methohexital 171,585 0.171585 1,939 
Ketorolac 138,031.4 0.138031 5,400 
Esmolol 66,228 0.066228 2,515 
 
